Related Experiment Video

Updated: Aug 30, 2026

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

No effect of simvastatin treatment on insulin sensitivity in patients with primary hypercholesterolemia

Hasan Altunbaş1, Mustafa Kemal Balci, Umit Karayalçin

  • 1Department of Internal Medicine, Division of Endocrinology and Metabolism, Akdeniz University School of Medicine, Antalya, Turkey.

Endocrine Research
|October 11, 2003
PubMed
Abstract

Insights

Short-term simvastatin use in hypercholesterolemic patients did not alter insulin sensitivity. This study found no significant changes in glucose disposal rate (M value) after two months of simvastatin treatment.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Statins possess non-lipid effects impacting atheromatous plaque formation and progression.
  • Insulin resistance and hyperinsulinemia may adversely affect the arterial wall.
  • Statins' potential to inhibit insulin signaling in vascular cells warrants investigation into their effect on insulin sensitivity.

Purpose of the Study:

  • To investigate the impact of simvastatin on insulin sensitivity in patients with hypercholesterolemia.
  • To clarify the controversial role of statins in modulating insulin sensitivity.

Main Methods:

  • Eighteen hypercholesterolemic patients were randomized into simvastatin (20 mg/day) and placebo groups for 2 months.
  • Lipid profiles (total, LDL, HDL cholesterol) were measured.
  • Insulin sensitivity was assessed using the euglycemic hyperinsulinemic clamp technique (glucose disposal rate, M).

Main Results:

  • Simvastatin significantly reduced total, LDL, and HDL cholesterol levels.
  • The M value showed an insignificant decrease in the simvastatin group and an increase in the placebo group.
  • No significant effect of short-term simvastatin treatment on insulin sensitivity was observed.

Conclusions:

  • Short-term simvastatin treatment does not appear to affect insulin sensitivity in hypercholesterolemic patients, as measured by the euglycemic hyperinsulinemic clamp.
  • Further research with higher simvastatin doses and longer treatment durations is recommended to fully elucidate its effects on insulin sensitivity.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...